ORKA
Oruka Therapeutics, Inc. (ORKA) reported net income of -$105.43M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$105.43M | -25.9% |
| FY 2024 | -$83.72M | -1468.2% |
| FY 2023 | -$5.34M | +46.2% |
| FY 2022 | -$9.93M | +48.6% |
| FY 2021 | -$19.32M | -98.4% |
| FY 2020 | -$9.74M | -77.6% |
| FY 2019 | -$5.48M | +30.9% |
| FY 2018 | -$7.93M | +57.1% |
| FY 2017 |
Oruka Therapeutics, Inc. (ORKA) reported net income of -$105.43M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2011 and fiscal 2025, Oruka Therapeutics, Inc.'s net income declined from -$5.36M to -$105.43M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$18.49M |
| -12.4% |
| FY 2016 | -$16.44M | -43.7% |
| FY 2015 | -$11.45M | -18.1% |
| FY 2014 | -$9.69M | -39.6% |
| FY 2013 | -$6.94M | -60.6% |
| FY 2012 | -$4.32M | +19.5% |
| FY 2011 | -$5.36M | - |